— Know what they know.
Not Investment Advice
Also trades as: RVPHW (NASDAQ) · $vol 0M

RVPH OTC

Reviva Pharmaceuticals Holdings, Inc.
1W: -2.2% 1M: -5.9% 3M: +9.8% YTD: +45.2% 1Y: -33.4% 3Y: -89.9% 5Y: -87.0%
$0.38
-0.04 (-10.03%)
 
Weekly Expected Move ±8.0%
$0 $0 $0 $0 $0
OTC · Healthcare · Biotechnology · Tech Score Strong Sell · Power 33 · $5.0M mcap · 12M float · 0.319% daily turnover · Short 29% of daily vol
Credit Risk of going bust: not rated, debt is over 20 times the stock's value Debt: 100.0% of company value Bonds: none of note held by US funds details ▾
Not rated: debt is over 20 times the stock market value, where the model breaks down (deep distress or a data error). Altman Z'' -21.86.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Oct Typical
⛈️
Stormy
-26.7% YTD avg
Midterm Year
☀️
Sunny
+20.3% YTD avg
2026 Now
☀️
Sunny
Above typical
20yr Avg YTD
-26.7%
Day 206 of 252
Midterm Year YTD
+20.3%
Presidential cycle avg
2026 YTD
+45.2%
Above 20yr avg
Typical Vol
133%
Annualized
Monthly Weather Forecast
Jan
20yr
⛈️
-6.3%
Midterm
⛈️
-18.9%
62% win 71% vol
Feb
20yr
💨
-10.2%
Midterm
⛈️
-16.5%
62% win 2367% vol
Mar
20yr
⛈️
-21.7%
Midterm
⛈️
-15.2%
25% win 110% vol
Apr
20yr
💨
-11.8%
Midterm
⛈️
-33.5%
62% win 154% vol
May
20yr
⛈️
-20.8%
Midterm
⛈️
-35.2%
25% win 126% vol
Jun
20yr
⛈️
-30.3%
Midterm
⛈️
-58.6%
38% win 116% vol
Jul
20yr
⛈️
-38.7%
Midterm
⛈️
-75.5%
12% win 83% vol
Aug
20yr
💨
-32.3%
Midterm
⛈️
-24.5%
50% win 150% vol
Sep
20yr
🌫️
-31.5%
Midterm
⛈️
-45.2%
38% win 92% vol
Oct
20yr
💨
-20.3%
Midterm
☀️
+35.2%
44% win 133% vol
Now: -4.3%
Nov
20yr
⛈️
-25.2%
Midterm
☀️
+26.6%
50% win 91% vol
Dec
20yr
💨
+0.7%
Midterm
💨
+8.2%
62% win 121% vol
Seasonality (20yr)
Updated: 2026-10-27
YTD: +45.2%

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms